Obstructive sleep apnea (OSA) is a common disorder characterized by obstructive apneas, hypopneas, and respiratory effort related arousals during sleep. Treatment of OSA is important because untreated patients have potential adverse clinical outcomes, such as excessive daytime sleepiness, metabolic dysfunction, cardiovascular disease, and mortality. Therefore, OSA should be considered as a chronic disease that requires long-term and multidisciplinary care. Positive airway pressure (PAP) therapy is the mainstay of treatment for OSA in adults. Alternative therapies include oral appliance, behavioral modification, and upper airway surgery. The treatment of OSA in adults is reviewed here with focus on PAP therapy.
Adult* ; Apnea ; Arousal ; Cardiovascular Diseases ; Chronic Disease ; Complementary Therapies ; Humans ; Mortality ; Sleep Apnea, Obstructive*

Objectives: We analyzed theta-band phase synchrony (TBPS) under reduced and ordinary flicker lighting to determine the effect of light flickers on neurocognitive processes. Methods: Nineteen healthy participants (mean age, 30.4±4.5 years; male, 63.2%) performed the Sternberg working memory tasks with event-related potential recording under reduced and control flicker conditions, respectively. We measured the P300 amplitude during memory retrieval, and for TBPS analysis, we calculated the weighted phase lag index within the P300 time window. Furthermore, we used standardized low-resolution brain electromagnetic tomography (sLORETA) to determine differences in functional cortical source connectivity between the two flicker conditions. Results: The hit rate (F1,18=0.862, p=0.365), reaction time (F1,18=0.021, p=0.887), and P300 amplitude (F1,18=3.992, p=0.061) did not differ between the two flicker conditions. However, connectivity analysis at the scalp level showed that TBPS under reduced flicker lighting was significantly higher than that under control flicker lighting at higher memory loads (p=0.002). Cortical source imaging with sLORETA confirmed that reduced flicker lighting significantly increased TBPS between the left prefrontal cortex and right hippocampus compared with control flicker lighting (false discovery rate<0.1). Conclusions Reduced flicker lighting enhanced TBPS during the working memory task compared with control flicker lighting. Reduced flicker light may improve cognitive functioning by facilitating information transfer within the brain network. Flicker conditions should be considered when optimizing lighting, especially in environments demanding high-level cognitive performance.

Objectives: We analyzed theta-band phase synchrony (TBPS) under reduced and ordinary flicker lighting to determine the effect of light flickers on neurocognitive processes. Methods: Nineteen healthy participants (mean age, 30.4±4.5 years; male, 63.2%) performed the Sternberg working memory tasks with event-related potential recording under reduced and control flicker conditions, respectively. We measured the P300 amplitude during memory retrieval, and for TBPS analysis, we calculated the weighted phase lag index within the P300 time window. Furthermore, we used standardized low-resolution brain electromagnetic tomography (sLORETA) to determine differences in functional cortical source connectivity between the two flicker conditions. Results: The hit rate (F1,18=0.862, p=0.365), reaction time (F1,18=0.021, p=0.887), and P300 amplitude (F1,18=3.992, p=0.061) did not differ between the two flicker conditions. However, connectivity analysis at the scalp level showed that TBPS under reduced flicker lighting was significantly higher than that under control flicker lighting at higher memory loads (p=0.002). Cortical source imaging with sLORETA confirmed that reduced flicker lighting significantly increased TBPS between the left prefrontal cortex and right hippocampus compared with control flicker lighting (false discovery rate<0.1). Conclusions Reduced flicker lighting enhanced TBPS during the working memory task compared with control flicker lighting. Reduced flicker light may improve cognitive functioning by facilitating information transfer within the brain network. Flicker conditions should be considered when optimizing lighting, especially in environments demanding high-level cognitive performance.

Ramucirumab is a vascular endothelial growth factor (VEGF) receptor-2 inhibiting monoclonal antibody for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Some VEGF inhibitors are known to increase the risk of ischemic stroke; however, their association with ramucirumab remains controversial. To the best of our knowledge, only two cases of ischemic stroke following ramucirumab treatment have been reported worldwide. We herein present the first case of acute cerebral infarction secondary to ramucirumab in Korea.

Ramucirumab is a vascular endothelial growth factor (VEGF) receptor-2 inhibiting monoclonal antibody for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Some VEGF inhibitors are known to increase the risk of ischemic stroke; however, their association with ramucirumab remains controversial. To the best of our knowledge, only two cases of ischemic stroke following ramucirumab treatment have been reported worldwide. We herein present the first case of acute cerebral infarction secondary to ramucirumab in Korea.

Ramucirumab is a vascular endothelial growth factor (VEGF) receptor-2 inhibiting monoclonal antibody for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Some VEGF inhibitors are known to increase the risk of ischemic stroke; however, their association with ramucirumab remains controversial. To the best of our knowledge, only two cases of ischemic stroke following ramucirumab treatment have been reported worldwide. We herein present the first case of acute cerebral infarction secondary to ramucirumab in Korea.

Ramucirumab is a vascular endothelial growth factor (VEGF) receptor-2 inhibiting monoclonal antibody for the treatment of gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Some VEGF inhibitors are known to increase the risk of ischemic stroke; however, their association with ramucirumab remains controversial. To the best of our knowledge, only two cases of ischemic stroke following ramucirumab treatment have been reported worldwide. We herein present the first case of acute cerebral infarction secondary to ramucirumab in Korea.

No abstract available.
Hemorrhage ; Hypotension, Orthostatic ; Pons